CERT

Certara Inc
NASDAQHEALTHCAREHEALTH INFORMATION SERVICES

Key Statistics

Market Cap
$1.84B
P/E Ratio
—
EPS
$-0.18
Beta
1.25
52W High
$12.61
52W Low
$4.45
50-Day MA
$9.26
200-Day MA
$7.30
Dividend Yield
—
Profit Margin
-15.60%
Forward P/E
27.17
PEG Ratio
—

About Certara Inc

Certara Inc. provides software products and technology services to clients for biosimulation in drug discovery, preclinical and clinical research, regulatory filings, and market access. The company is headquartered in Princeton, New Jersey.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$412.03M
Gross Profit (TTM)$258.40M
EBITDA$80.20M
Operating Margin2.45%
Return on Equity-2.70%
Return on Assets0.27%
Revenue/Share (TTM)$2.64
Book Value$6.41
Price-to-Book1.90
Price-to-Sales (TTM)4.46
EV/Revenue4.568
EV/EBITDA22.75
Quarterly Earnings Growth (YoY)285.20%
Quarterly Revenue Growth (YoY)-9.30%
Shares Outstanding$152.54M
Float$111.96M
% Insiders2.73%
% Institutions110.83%

Historical Volatility

HV 10-Day
59.83%
HV 20-Day
50.15%
HV 30-Day
57.77%
HV 60-Day
52.87%
HV Rank
64.3%

Volatility is currently expanding

Analyst Ratings

Consensus ($9.17 target)
4
Buy
9
Hold

Latest News

Certara, Inc. (CERT) Q3 2026 Earnings Call Transcript

Certara, Inc. ( CERT ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Jon Resnick - CEO & Director Faiz Mohammed - Interim CFO, Senior VP of Finance, Treasurer and Principal Financial & Accounting Officer Conference Call Participants Jay Liu Tucker Remmers - UBS Investment Bank, Research Division Dylan Finley - Leerink Partners LLC, Research Division David Windley - Jefferies LLC, Research Division Brendan Smith - TD Cowen, Research Division Katherine Bennorth - Morgan Stanley, Research Division Matthew Hewitt - Craig-Hallum Capital Group LLC, Research Division Christine Rains - William Blair & Company L.L.C., Research Division Luke Sergott - Barclays Bank PLC, Research Division Christopher Charlton - BMO Capital Markets Equity Research Presentation Operator Good day, and thank you for standing by.

Seeking Alpha11/6/2026Neutral
Certara Q3 Earnings Call Highlights

Certara NASDAQ: CERT reported 4% revenue growth in the third quarter of 2026 as double-digit software growth offset a decline in services, while cost reductions and a favorable sales mix helped lift profitability.

MarketBeat11/5/2026Positive
Certara Reports Third Quarter 2026 Financial Results

Certara delivers a solid quarter with double-digit software revenue growth Updates 2026 financial outlook Appoints Grant Peterson Chief Product Officer Company to host conference call and webcast today at 8:30 a.m. ET  RADNOR, Pa.

GlobeNewsWire11/5/2026Neutral
Certara Q2 Earnings Call Highlights

Certara NASDAQ: CERT reported second-quarter 2026 revenue of $93.3 million, up 1% year over year, as software growth offset a decline in services revenue. Management reaffirmed its full-year revenue outlook while outlining further changes to its commercial organization, cost structure and artificial intelligence strategy.

MarketBeat8/4/2026Neutral
Certara Reports Second Quarter 2026 Financial Results

Appoints Julien Perrier Chief Commercial Officer Completes previously authorized $100 million share repurchase program; Board authorizes additional $50 million under repurchase program Reaffirms 2026 revenue guidance RADNOR, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its second quarter 2026 financial results.

GlobeNewsWire8/4/2026Neutral

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CERT and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 11/7/2026